Adocia announced the expiration of Sanofi's three-year exclusive right to negotiate a partnership for M1Pram, a fixed combination of insulin and amylin analogs for type 1 diabetes. The exclusivity was granted in July 2023 in return for a payment of €10 million. Adocia now retains global rights to M1Pram and has put its development on hold while it evaluates the path forward as the type 1 diabetes treatment landscape evolves. The company is focusing on its metabolic peptide delivery platforms, particularly BioChaperone. In a Phase 2a trial, M1Pram demonstrated a significant reduction in body weight of 5.56 kg for participants with a BMI over 30 kg/m² after 16 weeks compared to insulin lispro, along with a 21% reduction in prandial insulin doses while maintaining glycemic control without increasing hypoglycemia risk.
AdociaAdocia regains full global rights to M1Pram, which showed strong weight loss and insulin dose reduction in Phase 2a.
Sanofi SASanofi loses exclusive negotiation rights for M1Pram, potentially missing a promising diabetes asset.